Ownership history in CITADEL ADVISORS LLC Β· 61 quarters on record
This page tracks every 13F SEC filing in which CITADEL ADVISORS LLC reported a position in RHYTHM PHARMACEUTICALS INC (RYTM). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π CITADEL ADVISORS LLC outperformed the S&P 500 by +35.5% annually on this RYTM position. Timing score: 63% (37/59 decisions correct). Average cost basis: $36.77. Maximum drawdown during holding period: β86.7%.
π₯ Exceptional β beat the S&P 500 by 35.5% per year on this position.
59 quarters analyzed
β
Decent timing β more right than wrong on entries and exits.
37 of 59 add/trim decisions correct
Best entry: $11.52 (2022 Q1) Β· Worst: $107.04 (2025 Q4)
πͺ Held through 2 major drawdowns (>20%).
27 adds Β· 34 trims. Bought during 3 of 13 down-price quarters. π Predominantly trimming β distribution phase.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.0% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size